Important Notice for TransMedics Group, Inc. (TMDX) Shareholders:
New York, NY – The Gross Law Firm, a leading national shareholder rights law firm, announces that it has commenced an investigation on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) who purchased shares during the period between February 17, 2021, and March 15, 2022. The investigation focuses on allegations that the Company and its executives may have violated federal securities laws.
Background:
TransMedics Group, Inc. is a medical technology company that develops, manufactures, markets, and sells organ care solutions for abdominal organs, including the Organ Care System for the liver, heart, and lungs. The Company’s products are designed to extend the viability of organs outside the body, improving the chances of successful transplantation.
Investigation Allegations:
The investigation concerns potential securities laws violations regarding the Company’s financial statements and disclosures. Specifically, the investigation focuses on whether TransMedics and its executives made false and/or misleading statements and/or failed to disclose material information during the Class Period about the Company’s business, operations, and financial condition.
Potential Impact on Shareholders:
Shareholders who purchased TransMedics shares during the Class Period may be able to recover their losses through the appointment of a lead plaintiff in this action. The lead plaintiff is a representative party acting on behalf of other class members in this lawsuit. If you wish to serve as the lead plaintiff, you must meet certain legal qualifications and must be willing to cooperate with your counsel in advancing the litigation.
- Shareholders may be able to recover damages for their losses, including any losses sustained in the sale of their shares of TMDX stock.
- Shareholders may also be entitled to a court-appointed representative to act on their behalf and protect their interests.
- The lead plaintiff will be responsible for working with the law firm to direct the litigation and make important decisions.
Impact on the World:
The implications of this investigation extend beyond TransMedics shareholders. The medical community and patients worldwide stand to be affected as the investigation unfolds. TransMedics’ organ care solutions have the potential to save countless lives, and any misconduct or misrepresentation could hinder the progress and trust in the medical technology industry.
How to Participate:
If you wish to discuss this investigation or have questions about your rights and interests, please contact The Gross Law Firm as soon as possible at 888-229-9110, or email [email protected]. You may also visit the firm’s website at www.grosslawfirm.com for more information.
If you are a TransMedics shareholder and wish to join this action, please submit your information using the form on the firm’s Shareholder Information form on the firm’s website. For more information about the investigation and your rights and potential remedies, visit our website at www.grosslawfirm.com/transmedics. The deadline to request appointment as lead plaintiff is April 18, 2025.
The Gross Law Firm represents investors worldwide, and the firm’s securities lawyers have filed and led hundreds of securities class actions on behalf of shareholders. If you have any questions about this notice or your rights, please contact The Gross Law Firm for a free consultation.
Conclusion:
TransMedics Group, Inc. shareholders who purchased shares during the specified period are encouraged to contact The Gross Law Firm regarding the investigation into potential securities laws violations. Shareholders may be able to recover damages and potentially serve as the lead plaintiff in this action. The implications of this investigation reach far beyond the shareholder community, affecting the medical community and patients worldwide. For more information, please visit www.grosslawfirm.com/transmedics or contact The Gross Law Firm at 888-229-9110 or [email protected].
